Here, we propose PMEPA1 isoforms (a and b) as candidate biomarkers in order to monitor prostate cancer progression in castration resistance and metastasis via a mechanistic model in which increased PMEPA1-a/PMEPA1-b expression, along with reduced PMEPA1-b expression, drives the progression of prostate cancer. This evidence concerns the gene PMEPA1 and prostate cancer.